Telomir Pharmaceuticals, Inc. 8-K

What Happened

• On June 15, 2026, Telomir Pharmaceuticals announced the peer‑reviewed publication of preclinical data on Telomir‑Zn in the journal Biomedicine & Pharmacotherapy.
• The manuscript, titled “Telomir‑Zn Restores Glucose Homeostasis and Reduces Insulin Resistance in a Diet‑Induced Zebrafish Model of Type 2 Diabetes,” reports dose‑dependent improvements in fasting blood glucose, glucose tolerance, fasting insulin, and insulin resistance as measured by HOMA‑IR.
• The company noted this is its second peer‑reviewed publication in 2026 and reiterated that Telomir‑Zn has received IND clearance from the FDA for the Phase 1/2 TELO‑001 trial in patients with advanced or metastatic triple‑negative breast cancer.

Key Details

• Date of disclosure: June 15, 2026.
• Journal: Biomedicine & Pharmacotherapy; manuscript title as stated above.
• Preclinical model and endpoints: diet‑induced zebrafish model of Type 2 diabetes; dose‑dependent improvements in fasting blood glucose, glucose tolerance, fasting insulin, and HOMA‑IR.
• Regulatory status: Telomir‑Zn has IND clearance for a Phase 1/2 clinical trial (TELO‑001) in advanced/metastatic triple‑negative breast cancer.

Why It Matters

• The publication provides additional peer‑reviewed preclinical evidence supporting Telomir‑Zn’s proposed mechanism (modulation of intracellular metal homeostasis), which the company cites as scientific rationale for its lead clinical program.
• For investors, this is a nonclinical milestone that strengthens the scientific record but does not represent clinical efficacy in humans; the program’s progress now rests on the outcome of the FDA‑cleared Phase 1/2 clinical trial (TELO‑001).